News | August 02, 2023
Bliss GVS Pharma Q1 FY2024 consolidated PAT up at Rs. 14.68 Cr
The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023
The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023
Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023)
JDHL has a strong reputation as an end-to-end design-focused manufacturer of electro-medical devices
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision
The company has secured 506 marketing approvals for its oncology products across 76 countries.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Take proper precautions and seek timely treatment!
Subscribe To Our Newsletter & Stay Updated
